Brokerages expect Bruker (NASDAQ:BRKR) to report sales of $434.72 million for the current quarter, Zacks Investment Research reports. Six analysts have issued estimates for Bruker’s earnings, with estimates ranging from $427.50 million to $444.00 million. Bruker posted sales of $414.90 million in the same quarter last year, which suggests a positive year-over-year growth rate of 4.8%. The firm is scheduled to issue its next quarterly earnings report on Thursday, August 2nd.
On average, analysts expect that Bruker will report full-year sales of $1.89 billion for the current year, with estimates ranging from $1.89 billion to $1.90 billion. For the next financial year, analysts forecast that the company will report sales of $1.96 billion per share, with estimates ranging from $1.95 billion to $1.98 billion. Zacks’ sales calculations are an average based on a survey of research analysts that that provide coverage for Bruker.
Get Bruker alerts:Bruker (NASDAQ:BRKR) last released its earnings results on Thursday, May 3rd. The medical research company reported $0.24 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.22 by $0.02. Bruker had a net margin of 4.63% and a return on equity of 27.04%. The firm had revenue of $431.70 million during the quarter, compared to the consensus estimate of $419.25 million. During the same period in the prior year, the firm earned $0.19 EPS. The company’s revenue was up 12.2% compared to the same quarter last year.
BRKR has been the subject of several analyst reports. Morgan Stanley cut their price objective on shares of Bruker from $32.00 to $31.00 and set an “equal weight” rating for the company in a report on Wednesday, April 11th. BidaskClub downgraded shares of Bruker from a “buy” rating to a “hold” rating in a report on Saturday, February 10th. Leerink Swann raised their price objective on shares of Bruker from $32.00 to $34.00 and gave the stock a “market perform” rating in a report on Friday, February 9th. Bank of America cut their price objective on shares of Bruker from $37.00 to $34.00 and set a “neutral” rating for the company in a report on Friday, May 4th. Finally, Zacks Investment Research upgraded shares of Bruker from a “hold” rating to a “buy” rating and set a $34.00 target price on the stock in a research note on Tuesday, May 8th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and three have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $32.91.
Bruker traded down $0.27, hitting $30.11, on Friday, according to MarketBeat Ratings. The company’s stock had a trading volume of 13,993 shares, compared to its average volume of 629,457. The company has a market cap of $4.74 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 2.00 and a beta of 1.14. Bruker has a 12 month low of $26.76 and a 12 month high of $36.53. The company has a current ratio of 2.22, a quick ratio of 1.29 and a debt-to-equity ratio of 0.26.
The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 22nd. Stockholders of record on Monday, June 4th will be given a dividend of $0.04 per share. This represents a $0.16 annualized dividend and a dividend yield of 0.53%. The ex-dividend date is Friday, June 1st. Bruker’s dividend payout ratio (DPR) is currently 13.22%.
A number of large investors have recently modified their holdings of the stock. BlackRock Inc. raised its position in Bruker by 1.8% in the 1st quarter. BlackRock Inc. now owns 5,267,689 shares of the medical research company’s stock worth $157,609,000 after purchasing an additional 93,829 shares during the period. Russell Investments Group Ltd. raised its position in Bruker by 1.3% in the 1st quarter. Russell Investments Group Ltd. now owns 1,483,860 shares of the medical research company’s stock worth $44,397,000 after purchasing an additional 19,226 shares during the period. Boston Partners raised its position in Bruker by 2.7% in the 1st quarter. Boston Partners now owns 1,297,471 shares of the medical research company’s stock worth $38,821,000 after purchasing an additional 34,578 shares during the period. Geode Capital Management LLC raised its position in Bruker by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 1,294,131 shares of the medical research company’s stock worth $44,414,000 after purchasing an additional 31,742 shares during the period. Finally, Dimensional Fund Advisors LP raised its position in Bruker by 1.9% in the 1st quarter. Dimensional Fund Advisors LP now owns 958,525 shares of the medical research company’s stock worth $28,679,000 after purchasing an additional 17,812 shares during the period. Institutional investors own 65.55% of the company’s stock.
About Bruker
Bruker Corporation manufactures and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates in two segments, Bruker Scientific Instruments, and Bruker Energy & Supercon Technologies. It offers life science tools based on magnetic resonance technology; life science mass spectrometry and ion mobility spectrometry systems; infrared spectroscopy and radiological/nuclear detectors for chemical, biological, radiological, nuclear, and explosive detection in emergency response, homeland security, and defense applications; and research, analytical, and process analysis instruments and solutions based on infrared and Raman molecular spectroscopy technologies.
Get a free copy of the Zacks research report on Bruker (BRKR)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment